CJC-1295 research guide for Monteros. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
Most researchers searching for CJC-1295 in Monteros soon discover that local retail options are essentially nonexistent. This matters because CJC-1295 quality ranges widely across the market — from analytically confirmed high-purity product to products with serious contamination — and the vendor controls every quality variable. A legitimate CJC-1295 supplier's COA must contain HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all corresponding to the vial you receive. This guide walks Monteros researchers through that evaluation process and explains what quality documentation for CJC-1295 should look like.
Understanding CJC-1295 — Biology & Evidence
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Monteros researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
Buying CJC-1295: Quality Markers to Look For
Before assessing any particular supplier, establish a quality benchmark — so you can recognise whether a vendor meets it. When reviewing a CJC-1295 COA, verify: the batch number corresponds to your vial, HPLC purity is ≥98%, mass spec identifies the correct molecular weight, and endotoxin levels are at acceptable levels for the intended application. Signs of a credible vendor beyond COA quality: multi-year operating history, knowledgeable support capable of explaining COA data, and temperature-appropriate packaging with desiccant. For Monteros researchers making a first CJC-1295 purchase: apply these quality criteria before ordering, begin with a small order, and verify batch traceability on arrival before use.
Order CJC-1295 — ships to Monteros
COA-verified · International tracking · Research grade
CJC-1295 is sold for research purposes only and is not approved for human use by the FDA or comparable health authorities — all information here is provided for educational purposes. Reconstitute CJC-1295 with bacteriostatic water at an appropriate concentration for your protocol; a standard 5mg vial with 2mL bac water yields 2.5mg/mL — or 25mcg per insulin syringe unit. Endotoxin testing in the CJC-1295 COA is not optional — gram-negative bacterial endotoxins can trigger dangerous immune responses at trace quantities, and no discount compensates for this missing data. The research literature on CJC-1295 should be reviewed carefully before planning any study — study methodologies, dosing, and endpoints vary significantly and conclusions do not uniformly extrapolate.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
